John Maslowski

John Maslowski is President and Chief Executive Officer of Forge Biologics, previously serving as Forge’s inaugural Chief Commercial Officer. He brings extensive cell and gene therapy industry experience to the company. He previously served as the President and Chief Executive Officer of Castle Creek Biosciences, Inc. and served in the same role at Fibrocell Science, Inc. (a NASDAQ rare disease cell and gene therapy company) until Fibrocell was acquired in 2019. He previously served as Senior Vice President of Scientific Affairs and Vice President of Operations there while at Fibrocell. Mr. Maslowski was instrumental in advancing D-Fi, a genetically modified autologous fibroblast therapy to pivotal clinical trials, and LAVIV®, a non-modified autologous fibroblast therapy, through U.S. FDA approval and commercialization. Mr. Maslowski serves on the board of debra of America, a leading advocacy organization with the mission to improve the lives of patients suffering from epidermolysis bullosa (EB), and the Board of Advisors for Life Science Cares Philadelphia, an advocacy group dedicated to fighting poverty and inequality in the local region. He previously served on the board of the Alliance for Regenerative Medicine. He has been a trusted advisor to industry leaders through past and current board and advisory roles, sharing his 25+ years of experience at major pharmaceutical companies which also include Wyeth Pharmaceuticals, Merck & Co., Inc., and Teva Pharmaceuticals Industries Ltd. Mr. Maslowski received his B.S. in biology from Ursinus College and his M.S. in microbiology from Villanova University.